Invivyd (IVVD) said Tuesday that it plans to launch a mid-stage clinical trial, along with the SPEAR Study Group, that assesses the safety, translational biology, and exploratory clinical efficacy of investigational antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.

The trial will evaluate multiple high doses of the antibody across many months of therapy, the company said.

The mid-stage trial is expected to begin by mid-2026, with further details to be announced in the coming months, Invivyd said.